| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile |
| 30 Oct 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 29, 2026, and effective as of January 1, 2027 (the “Effective Date”), is made by and between Harmony Biosciences Management, Inc., a Delaware... |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 13 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027. |
| 18 Sep 2026 |
Form 4: Budur Kumar, CHIEF MEDICAL OFFICER
Received 1,800 shares by exercise or conversion ($54.9K) · Sold 1,800 shares ($77.4K) · Received 800 shares by exercise or conversion ($24.4K) · 3 more |
| 18 Sep 2026 | 144 |
| 17 Sep 2026 | 144 |
| 16 Sep 2026 | 144 |
| 09 Sep 2026 |
Form 4: Budur Kumar, CHIEF MEDICAL OFFICER
Sold 5,500 shares ($231K) · Sold 28,454 shares ($1.22M) · Received 22,954 shares by exercise or conversion ($700K) |
| 08 Sep 2026 | 144 |
| 04 Sep 2026 | 144 |
| 07 Aug 2026 | 144 |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile |
| 31 Jul 2026 | SCHEDULE 13G |
| 28 Jul 2026 | SCHEDULE 13G/A |
| 22 Jul 2026 |
Form 3: Mollichella Stephen M., INT PRINCIAL FINANCIAL OFFICER
Holds 2,506 shares of Common Stock |
| 16 Jul 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
This Separation Agreement (this “Agreement”) is entered into by and between Glenn Reicin (“Executive”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together the “Company”), effective as of July 16, 202... |
Loading...